Adding an AI tool to a research team is one thing. Building a company around AI also changes how the team organizes data, runs analyses, and records decisions.
At AgentCures, we use AI agents and version-controlled research as part of the same workflow. The aim is to make useful methods easier to repeat and give scientists more time for questions that need their judgment.
The AI-First Advantage
This approach can help in several practical ways:
Speed: Agents can run computational evaluations and prepare analyses while scientists focus on interpreting results and planning experiments.
Cost efficiency: Reusing tools and automating routine work can reduce the effort needed to support a research program.
Scalability: Models, assay templates, analysis code, and documentation methods can be shared across programs.
Reproducibility: Recording inputs, model versions, results, and decisions makes it easier to repeat an analysis and understand how a program changed.
What Investors Need to Assess
For investors, a platform raises different questions from a single drug candidate. Can the team reuse its methods on another target? Does a new program produce knowledge that helps the next one? Can it show that the tools improve decisions?
A portfolio of programs may spread some risk, but each still needs a sound biological rationale and experimental evidence. The platform’s value depends on how well it supports that work.
The AgentCures Model
We built AgentCures around AI agents, shared scientific tools, and a research record kept in Git. The agent can work across programs, document analyses, and update plans when new data arrives.
Software updates can make new capabilities available to research teams. Results from earlier programs can also help the team decide which methods to reuse and which need improvement.
What AI-First Does Not Mean
Biology is noisy, assays can mislead, and a promising prediction can fail in the lab. Scientists still need to judge whether a target matters, whether a result is reproducible, and whether the evidence supports further development.
Automation is useful when it makes those judgments better informed and leaves a record others can check.
Measuring the Contribution of AI
AI tools are becoming part of molecular design, data analysis, and trial planning. Teams need to measure their contribution in terms of research quality and program outcomes, as well as the time saved.
Building for the Future
We want research methods, data, and documents to stay connected as a program develops. Shared code and version control help with that. AI agents can then work within a record that scientists can inspect, correct, and build on.